Effectiveness and Tolerability of the ASAQ versus AL Association in Children 6-59 Months for the Treatment of Uncomplicated P. falciparum Malaria in Massakory (Chad)

Mahamat Moussa Hassane Taïsso; Issa Mahamat Souleymane; Hamit Mahamat Alio; Mahamat Saleh Issakha Diar; Djiddi Ali Sougoudi; Djimadoum Mbanga; Pascal Ringwald; Djimrassengarh Honoré; Issa Ali Haggar; Hassoumi Manah; Hassan Ahmat Mihedi; N’garadoum Olivier; David Koffi; Offianan André Touré; Djaman Allico Joseph

doi:doi:10.11648/j.ajbls.20210905.16

Effectiveness and Tolerability of the ASAQ versus AL Association in Children 6-59 Months for the Treatment of Uncomplicated P. falciparum Malaria in Massakory (Chad)

Mahamat Moussa Hassane Taïsso, Issa Mahamat Souleymane, Hamit Mahamat Alio, Mahamat Saleh Issakha Diar, Djiddi Ali Sougoudi, Djimadoum Mbanga, Pascal Ringwald, Djimrassengarh Honoré, Issa Ali Haggar, Hassoumi Manah, Hassan Ahmat Mihedi, N’garadoum Olivier, David Koffi, Offianan André Touré, Djaman Allico Joseph

Published in American Journal of Biomedical and Life Sciences (Volume 9, Issue 5)

Received: 23 September 2021 Accepted: 13 October 2021 Published: 21 October 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background and Objective: Artemisinin-based combination therapies are the first-line antimalarial drugs used to treat uncomplicated Plasmodium falciparum malaria in many endemic countries worldwide. This study was conducted to assess the efficacy and tolerability of two fixed-dose formulations of artesunate-amodiaquine and artemether-lumefantrine for the treatment of Plasmodium falciparum malaria in Chad. Méthodology and Results: A two-arm single cohort study was conducted assessing the efficacy artesunate-amodiaquine and artemether-lumefantrine for the treatment of children with uncomplicated falciparum malaria. This study was carried out from December 14, 2019 to March 14, 2020 at the Massakory I Health Center in Chad. Primary efficacy endpoint was day 28, parasitological cure rate. Secondary endpoints were parasite and fever clearance times and tolerability. A total of 113 patients were included, including 56 in the artesunate-amodiaquine arm and 57 in the artemether-lumefantrine arm. In intention to treat these patients, the Adequate Clinical and Parasitological Response on day 28 were 100% for the two groups. No early treatment failure was observed. The drugs were well tolerated and no serious adverse events were noted. Conclusion: Both forms of Artemisinin-based combination therapy were still effective and safe in the treatment of uncomplicated P. falciparum malaria in Chad. Further studies are warranted in different regions of Chad for monitoring of drug resistance.

Published in	American Journal of Biomedical and Life Sciences (Volume 9, Issue 5)
DOI	10.11648/j.ajbls.20210905.16
Page(s)	259-266
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Simple Malaria, Artésunate-Amodiaquine, Artemether-Lumefantrine, Plasmodium falciparum, Massakory, Chad

References

[1]	World Health Organization (WHO). (2017). World malaria report 2017. Geneva (http://apps.who.int/iris/bitstream/10665/259492/1/9789241565523-eng.pdf, accessed 19 December 2019) ISBN 978-92-4-156552-3.
[2]	World Health Organization. (‎2009)‎. Methods for surveillance of antimalarial drug efficacy. World Health Organization. https://apps.who.int/iris/handle/10665/44048 accessed 19 December 2019.
[3]	Noedl, H., Se, Y., Schaecher, K., Smith, B. L., Socheat, D., & Fukuda, M. M. (2008). Evidence of Artemisinin-Resistant Malaria in Western Cambodia. New England Journal of Medicine, 359 (24), 2619–2620.
[4]	Ashley, E. A., Dhorda, M., Fairhurst, R. M., Amaratunga, C., Lim, P., Suon, S., Sreng, S., Anderson, J. M., Mao, S., Sam, B., Sopha, C., Chuor, C. M., Nguon, C., Sovannaroth, S., Pukrittayakamee, S., Jittamala, P., Chotivanich, K., Chutasmit, K., Suchatsoonthorn, C., Runcharoen, R.,… Tracking Resistance to Artemisinin Collaboration (TRAC) (2014). Spread of artemisinin resistance in Plasmodium falciparum malaria. The New England journal of medicine, 371 (5), 411–423.
[5]	Menard, D., & Dondorp, A. (2017). Antimalarial Drug Resistance: A Threat to Malaria Elimination. Cold Spring Harbor perspectives in medicine, 7 (7), a025619.
[6]	Ménard, S., Ben Haddou, T., Ramadani, A. P., Ariey, F., Iriart, X., Beghain, J., Bouchier, C., Witkowski, B., Berry, A., Mercereau-Puijalon, O., & Benoit-Vical, F. (2015). Induction of Multidrug Tolerance in Plasmodium falciparum by Extended Artemisinin Pressure. Emerging infectious diseases, 21 (10), 1733–1741.
[7]	Takala-Harrison, S., & Laufer, M. K. (2015). Antimalarial drug resistance in Africa: key lessons for the future. Annals of the New York Academy of Sciences, 1342, 62–67.
[8]	Hamadou Bouare. (2018). Test d'efficacité Thérapeutique de la combinaison Arthemeter-Lumefantrine (AL) et Artesunate-Amodiaquine (ASAQ) dans le traitement du paludisme simple a P. falciparum à Sélingué et à Missira en 2016. These Med: Universite da Bamako (Mali), 120 p.
[9]	Souleymane ISSA M, Clément KH, Denis MM, et al. (2017) Therapeutic Efficacy of Artesunate-Amodiaquine and Polymorphism of Plasmodium falciparum k13-Propeller Gene in Pala (Tchad). Int J Open Access Clin Trials 1 (1): 1.
[10]	Mari De Wit, Anna Louise Funk, Krystel Moussally, David Aksanti Nkuba, Rubbis Siddiqui, Karla Bil, Erwan Piriou, Aldert Bart, Patrick Bahizi Bizoza and Teun Bousema. (2016). In vivo efficacy of artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo. Malaria Journal, 15 (1).
[11]	Issa Ibrahima, Ibrahim Maman Laminou, Eric Adehossi, Daou Maman, Saidou Boureima, Hama Kadri Harouna, Hamadou, Hassan Hamidou, Aboubacar Mahamadou, Idrissa Yacouba, Jackou Hadiza, Ilagouma Amadou Tidjani (2020) Study of therapeutic and therapeutic efficacy tolerance of artemether-lumefantrine and artesunate-amodiaquine in Niger. Bull Soc Pathol Exot doi 10.3166 / bspe-2020.
[12]	Sow D, Ndiaye JL, Sylla K, et al (2016) Evaluation of the efficacy and safety of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Med Santé Trop 26 (1): 45-50.
[13]	Ibrahim ML, Sadou F, Daou M, et al (2016) Comparison of therapeutic efficacy and tolerance of artemether-lumefantrine and artesunate-amodiaquine combinations in Niger. Mali Med 31 (1): 1-7.
[14]	Tinto, Halidou, Diallo Salou, Issaka Zongo, Issa Guiraud, Innocent Valea, Adama Kazienga, Hervé Kpoda, Herman Sorgho, Jean-Bosco Ouédraogo, Tinga Robert Guiguemdé and Umerto D’Alessandro. (2014). Effectiveness of artesunate-amodiaquine vs. artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non-inferiority randomised trial. Tropical Medicine & International Health, 19 (4), 469–475.
[15]	Sondo, P., Derra, K., Diallo-Nakanabo, S., Tarnagda, Z., Zampa, O., Kazienga, A., Valea, I., Sorgho, H., Owusu-Dabo, E., Ouedraogo, J. B., Guiguemde, T. R., & Tinto, H. (2015). Effectiveness and safety of artemether-lumefantrine versus artesunate-amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial. Malaria journal, 14, 325.
[16]	Houh, Y. K., Kim, K. E., Park, S., Hur, D. Y., Kim, S., Kim, D., Bang, S. I., Yang, Y., Park, H. J., & Cho, D. (2017). The Effects of Artemisinin on the Cytolytic Activity of Natural Killer (NK) Cells. International journal of molecular sciences, 18 (7), 1600.
[17]	Nji, A. M., Ali, I. M., Moyeh, M. N., Ngongang, E.-O., Ekollo, A. M., Chedjou, J.-P.,… Mbacham, W. F. (2015). Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children. Malaria Journal, 14 (1), 27.
[18]	Tchonfiene P. (2013). Efficacité et tolérance de Coarsucam ® dans le traitement du paludisme simple à Plasmodium falciparum (étude sur 117 enfants de 6-59 mois à Koyom; Mayo Kebbi Est). Thèse de doctorat en médecine, Université de N’Djaména (Tchad), 60 p.
[19]	Toure, O. A., Assi, S. B., N'Guessan, T. L., Adji, G. E., Ako, A. B., Brou, M. J., Ehouman, M. F., Gnamien, L. A., Coulibaly, M. A., Coulibaly, B., Beourou, S., Bassinka, I., Soumahoro, A., Kadjo, F., & Tano, M. A. (2014). Open-label, randomized, non-inferiority clinical trial of artesunate-amodiaquine versus artemether-lumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire. Malaria journal, 13, 439.
[20]	Bassi P, Osakwe AI, Suku C, et al (2016) Cohort event monitoring of patients treated for uncomplicated malaria with artemisinin-based combination therapies in selected hospitals and community pharmacies in Nigeria. Niger Postgrad Med J 23 (4): 172-181.
[21]	Grandesso F, Guindo O, Woi Messe L, et al (2018) Efficacy of artesunate-amodiaquine, dihydroartemisinin- piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger. Malar J 17 (1): 52.
[22]	Odhiambo G, Bergmann-Leitner E, Maraka M, Wanjala CNL, Duncan E, Waitumbi J, et al (2019) Correlation Between Malaria-Specific Antibody Profiles and Responses to Artemisinin Combination Therapy for Treatment of Uncomplicated Malaria in Western Kenya. J Infect Dis; 219 (12): 1969-79.
[23]	Faye, B., Kuété, T., Kiki-Barro, C. P., Tine, R. C., Nkoa, T., Ndiaye, J. L., Kakpo, C. A., Sylla, K., El Menan, H., Gaye, O., Faye, O., Same-Ekobo, A., & Moussa, K. (2012). Multicentre study evaluating the non-inferiority of the new paediatric formulation of artesunate/amodiaquine versus artemether/lumefantrine for the management of uncomplicated Plasmodium falciparum malaria in children in Cameroon, Ivory Coast and Senegal. Malaria journal, 11, 433.
[24]	Schramm, B., Valeh, P., Baudin, E., Mazinda, C. S., Smith, R., Pinoges, L., Dhorda, M., Boum, Y., 2nd, Sundaygar, T., Zolia, Y. M., Jones, J. J., Comte, E., Houzé, P., Jullien, V., Carn, G., Kiechel, J. R., Ashley, E. A., & Guérin, P. J. (2013). Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial. Malaria journal, 12, 251.
[25]	Lingani, M., Bonkian, L. N., Yerbanga, I., Kazienga, A., Valéa, I., Sorgho, H., Ouédraogo, J. B., Mens, P. F., Schallig, H., Ravinetto, R., d'Alessandro, U., & Tinto, H. (2020). In vivo/ex vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malaria journal, 19 (1), 8.

Cite This Article

Plain Text BibTeX RIS

APA Style

Mahamat Moussa Hassane Taïsso, Issa Mahamat Souleymane, Hamit Mahamat Alio, Mahamat Saleh Issakha Diar, Djiddi Ali Sougoudi, et al. (2021). Effectiveness and Tolerability of the ASAQ versus AL Association in Children 6-59 Months for the Treatment of Uncomplicated P. falciparum Malaria in Massakory (Chad). American Journal of Biomedical and Life Sciences, 9(5), 259-266. https://doi.org/10.11648/j.ajbls.20210905.16

Copy | Download

ACS Style

Mahamat Moussa Hassane Taïsso; Issa Mahamat Souleymane; Hamit Mahamat Alio; Mahamat Saleh Issakha Diar; Djiddi Ali Sougoudi, et al. Effectiveness and Tolerability of the ASAQ versus AL Association in Children 6-59 Months for the Treatment of Uncomplicated P. falciparum Malaria in Massakory (Chad). Am. J. Biomed. Life Sci. 2021, 9(5), 259-266. doi: 10.11648/j.ajbls.20210905.16

Copy | Download

AMA Style

Mahamat Moussa Hassane Taïsso, Issa Mahamat Souleymane, Hamit Mahamat Alio, Mahamat Saleh Issakha Diar, Djiddi Ali Sougoudi, et al. Effectiveness and Tolerability of the ASAQ versus AL Association in Children 6-59 Months for the Treatment of Uncomplicated P. falciparum Malaria in Massakory (Chad). Am J Biomed Life Sci. 2021;9(5):259-266. doi: 10.11648/j.ajbls.20210905.16

Copy | Download

@article{10.11648/j.ajbls.20210905.16,
  author = {Mahamat Moussa Hassane Taïsso and Issa Mahamat Souleymane and Hamit Mahamat Alio and Mahamat Saleh Issakha Diar and Djiddi Ali Sougoudi and Djimadoum Mbanga and Pascal Ringwald and Djimrassengarh Honoré and Issa Ali Haggar and Hassoumi Manah and Hassan Ahmat Mihedi and N’garadoum Olivier and David Koffi and Offianan André Touré and Djaman Allico Joseph},
  title = {Effectiveness and Tolerability of the ASAQ versus AL Association in Children 6-59 Months for the Treatment of Uncomplicated P. falciparum Malaria in Massakory (Chad)},
  journal = {American Journal of Biomedical and Life Sciences},
  volume = {9},
  number = {5},
  pages = {259-266},
  doi = {10.11648/j.ajbls.20210905.16},
  url = {https://doi.org/10.11648/j.ajbls.20210905.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20210905.16},
  abstract = {Background and Objective: Artemisinin-based combination therapies are the first-line antimalarial drugs used to treat uncomplicated Plasmodium falciparum malaria in many endemic countries worldwide. This study was conducted to assess the efficacy and tolerability of two fixed-dose formulations of artesunate-amodiaquine and artemether-lumefantrine for the treatment of Plasmodium falciparum malaria in Chad. Méthodology and Results: A two-arm single cohort study was conducted assessing the efficacy artesunate-amodiaquine and artemether-lumefantrine for the treatment of children with uncomplicated falciparum malaria. This study was carried out from December 14, 2019 to March 14, 2020 at the Massakory I Health Center in Chad. Primary efficacy endpoint was day 28, parasitological cure rate. Secondary endpoints were parasite and fever clearance times and tolerability. A total of 113 patients were included, including 56 in the artesunate-amodiaquine arm and 57 in the artemether-lumefantrine arm. In intention to treat these patients, the Adequate Clinical and Parasitological Response on day 28 were 100% for the two groups. No early treatment failure was observed. The drugs were well tolerated and no serious adverse events were noted. Conclusion: Both forms of Artemisinin-based combination therapy were still effective and safe in the treatment of uncomplicated P. falciparum malaria in Chad. Further studies are warranted in different regions of Chad for monitoring of drug resistance.},
 year = {2021}
}

Copy | Download

TY - JOUR
T1 - Effectiveness and Tolerability of the ASAQ versus AL Association in Children 6-59 Months for the Treatment of Uncomplicated P. falciparum Malaria in Massakory (Chad)
AU - Mahamat Moussa Hassane Taïsso
AU - Issa Mahamat Souleymane
AU - Hamit Mahamat Alio
AU - Mahamat Saleh Issakha Diar
AU - Djiddi Ali Sougoudi
AU - Djimadoum Mbanga
AU - Pascal Ringwald
AU - Djimrassengarh Honoré
AU - Issa Ali Haggar
AU - Hassoumi Manah
AU - Hassan Ahmat Mihedi
AU - N’garadoum Olivier
AU - David Koffi
AU - Offianan André Touré
AU - Djaman Allico Joseph
Y1 - 2021/10/21
PY - 2021
N1 - https://doi.org/10.11648/j.ajbls.20210905.16
DO - 10.11648/j.ajbls.20210905.16
T2 - American Journal of Biomedical and Life Sciences
JF - American Journal of Biomedical and Life Sciences
JO - American Journal of Biomedical and Life Sciences
SP - 259
EP - 266
PB - Science Publishing Group
SN - 2330-880X
UR - https://doi.org/10.11648/j.ajbls.20210905.16
AB - Background and Objective: Artemisinin-based combination therapies are the first-line antimalarial drugs used to treat uncomplicated Plasmodium falciparum malaria in many endemic countries worldwide. This study was conducted to assess the efficacy and tolerability of two fixed-dose formulations of artesunate-amodiaquine and artemether-lumefantrine for the treatment of Plasmodium falciparum malaria in Chad. Méthodology and Results: A two-arm single cohort study was conducted assessing the efficacy artesunate-amodiaquine and artemether-lumefantrine for the treatment of children with uncomplicated falciparum malaria. This study was carried out from December 14, 2019 to March 14, 2020 at the Massakory I Health Center in Chad. Primary efficacy endpoint was day 28, parasitological cure rate. Secondary endpoints were parasite and fever clearance times and tolerability. A total of 113 patients were included, including 56 in the artesunate-amodiaquine arm and 57 in the artemether-lumefantrine arm. In intention to treat these patients, the Adequate Clinical and Parasitological Response on day 28 were 100% for the two groups. No early treatment failure was observed. The drugs were well tolerated and no serious adverse events were noted. Conclusion: Both forms of Artemisinin-based combination therapy were still effective and safe in the treatment of uncomplicated P. falciparum malaria in Chad. Further studies are warranted in different regions of Chad for monitoring of drug resistance.
VL - 9
IS - 5
ER -

Copy | Download

Author Information

Mahamat Moussa Hassane Taïsso
Issa Mahamat Souleymane

Chad National Malaria Control Program, N’Djamena, Chad
Hamit Mahamat Alio

Faculty of Science and Human Health, University of N’Djamena, N’Djamena, Chad
Mahamat Saleh Issakha Diar

Chad National Malaria Control Program, N’Djamena, Chad
Djiddi Ali Sougoudi

Ministry of Health, Public and Human Solidarity, N’Djamena, Chad
Djimadoum Mbanga

Faculty of Science and Human Health, University of N’Djamena, N’Djamena, Chad
Pascal Ringwald

World Health Organization, Geneva, Switzerland
Djimrassengarh Honoré

World Health Organization, N’Djamena, Chad
Issa Ali Haggar

Ministry of Health, Public and Human Solidarity, N’Djamena, Chad
Hassoumi Manah

Ministry of Health, Public and Human Solidarity, N’Djamena, Chad
Hassan Ahmat Mihedi

Chad National Malaria Control Program, N’Djamena, Chad
N’garadoum Olivier

Chad National Malaria Control Program, N’Djamena, Chad
David Koffi

Department of Parasitology Mycology, Institute Pasteur, Abidjan, C?te d’Ivoire
Offianan André Touré

Department of Parasitology Mycology, Institute Pasteur, Abidjan, C?te d’Ivoire
Djaman Allico Joseph

Department of Parasitology Mycology, Institute Pasteur, Abidjan, C?te d’Ivoire

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Mahamat Moussa Hassane Taïsso, Issa Mahamat Souleymane, Hamit Mahamat Alio, Mahamat Saleh Issakha Diar, Djiddi Ali Sougoudi, et al. (2021). Effectiveness and Tolerability of the ASAQ versus AL Association in Children 6-59 Months for the Treatment of Uncomplicated P. falciparum Malaria in Massakory (Chad). American Journal of Biomedical and Life Sciences, 9(5), 259-266. https://doi.org/10.11648/j.ajbls.20210905.16

Copy | Download

ACS Style

Mahamat Moussa Hassane Taïsso; Issa Mahamat Souleymane; Hamit Mahamat Alio; Mahamat Saleh Issakha Diar; Djiddi Ali Sougoudi, et al. Effectiveness and Tolerability of the ASAQ versus AL Association in Children 6-59 Months for the Treatment of Uncomplicated P. falciparum Malaria in Massakory (Chad). Am. J. Biomed. Life Sci. 2021, 9(5), 259-266. doi: 10.11648/j.ajbls.20210905.16

Copy | Download

AMA Style

Mahamat Moussa Hassane Taïsso, Issa Mahamat Souleymane, Hamit Mahamat Alio, Mahamat Saleh Issakha Diar, Djiddi Ali Sougoudi, et al. Effectiveness and Tolerability of the ASAQ versus AL Association in Children 6-59 Months for the Treatment of Uncomplicated P. falciparum Malaria in Massakory (Chad). Am J Biomed Life Sci. 2021;9(5):259-266. doi: 10.11648/j.ajbls.20210905.16

Copy | Download

@article{10.11648/j.ajbls.20210905.16,
  author = {Mahamat Moussa Hassane Taïsso and Issa Mahamat Souleymane and Hamit Mahamat Alio and Mahamat Saleh Issakha Diar and Djiddi Ali Sougoudi and Djimadoum Mbanga and Pascal Ringwald and Djimrassengarh Honoré and Issa Ali Haggar and Hassoumi Manah and Hassan Ahmat Mihedi and N’garadoum Olivier and David Koffi and Offianan André Touré and Djaman Allico Joseph},
  title = {Effectiveness and Tolerability of the ASAQ versus AL Association in Children 6-59 Months for the Treatment of Uncomplicated P. falciparum Malaria in Massakory (Chad)},
  journal = {American Journal of Biomedical and Life Sciences},
  volume = {9},
  number = {5},
  pages = {259-266},
  doi = {10.11648/j.ajbls.20210905.16},
  url = {https://doi.org/10.11648/j.ajbls.20210905.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20210905.16},
  abstract = {Background and Objective: Artemisinin-based combination therapies are the first-line antimalarial drugs used to treat uncomplicated Plasmodium falciparum malaria in many endemic countries worldwide. This study was conducted to assess the efficacy and tolerability of two fixed-dose formulations of artesunate-amodiaquine and artemether-lumefantrine for the treatment of Plasmodium falciparum malaria in Chad. Méthodology and Results: A two-arm single cohort study was conducted assessing the efficacy artesunate-amodiaquine and artemether-lumefantrine for the treatment of children with uncomplicated falciparum malaria. This study was carried out from December 14, 2019 to March 14, 2020 at the Massakory I Health Center in Chad. Primary efficacy endpoint was day 28, parasitological cure rate. Secondary endpoints were parasite and fever clearance times and tolerability. A total of 113 patients were included, including 56 in the artesunate-amodiaquine arm and 57 in the artemether-lumefantrine arm. In intention to treat these patients, the Adequate Clinical and Parasitological Response on day 28 were 100% for the two groups. No early treatment failure was observed. The drugs were well tolerated and no serious adverse events were noted. Conclusion: Both forms of Artemisinin-based combination therapy were still effective and safe in the treatment of uncomplicated P. falciparum malaria in Chad. Further studies are warranted in different regions of Chad for monitoring of drug resistance.},
 year = {2021}
}

Copy | Download